Atul R Mahableshwarkar
Overview
Explore the profile of Atul R Mahableshwarkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gilbert D, Dubow J, Cunniff T, Wanaski S, Atkinson S, Mahableshwarkar A
Pediatrics
. 2023 Jan;
151(2).
PMID: 36628546
Background And Objectives: All US Food and Drug Administration-approved medications for Tourette syndrome are antipsychotics, and their use is limited by the risk of weight gain, metabolic changes, and drug-induced...
2.
Mahableshwarkar A, Affinito J, Reines E, Xu J, Nomikos G, Jacobsen P
CNS Spectr
. 2019 Jun;
25(3):352-362.
PMID: 31199210
Objectives: This study aimed to evaluate the risk of suicidal ideation and behavior associated with vortioxetine treatment in adults with major depressive disorder (MDD). Methods: Suicide-related events were evaluated post...
3.
Macek T, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, et al.
Schizophr Res
. 2018 Sep;
204:289-294.
PMID: 30190165
Introduction: TAK-063 is a potent, selective inhibitor of phosphodiesterase 10A, an enzyme selectively expressed in medium spiny neurons of the striatum. This randomized, parallel-group study evaluated the efficacy and safety...
4.
Fava M, Mahableshwarkar A, Jacobson W, Zhong W, Keefe R, Kurre Olsen C, et al.
Ann Clin Psychiatry
. 2018 Jul;
30(3):176-184.
PMID: 30028891
Background: Cognitive impairments, such as memory deficits and executive impairment, are common among patients with major depressive disorder (MDD) and can be captured with objective or subjective assessments. The aim...
5.
Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar A
Psychiatry Clin Neurosci
. 2017 Sep;
72(2):64-72.
PMID: 28858412
Aim: This study assessed the efficacy and safety of vortioxetine in adults with major depressive disorder. Methods: In this double-blind, placebo-controlled study, 600 patients with major depressive disorder were randomly...
6.
Mahableshwarkar A, Calabrese J, Macek T, Budur K, Adefuye A, Dong X, et al.
J Affect Disord
. 2017 Jun;
221:275-282.
PMID: 28662460
Background: The optimal long-term management strategy for bipolar I disorder patients is not yet established. Evidence supports the rationale for circadian rhythm regulation to prevent mood episode relapse in bipolar...
7.
Mahableshwarkar A, Zajecka J, Jacobson W, Chen Y, Keefe R
Neuropsychopharmacology
. 2016 Oct;
41(12):2961.
PMID: 27725683
No abstract available.
8.
Thase M, Mahableshwarkar A, Dragheim M, Loft H, Vieta E
Eur Neuropsychopharmacol
. 2016 May;
26(6):979-93.
PMID: 27139079
The efficacy and safety of vortioxetine, an antidepressant approved for the treatment of adults with major depressive disorder (MDD), was studied in 11 randomized, double-blind, placebo-controlled trials of 6/8 weeks׳...
9.
Jacobsen P, Mahableshwarkar A, Palo W, Chen Y, Dragheim M, Clayton A
CNS Spectr
. 2015 Nov;
21(5):367-378.
PMID: 26575433
Objective: Antidepressants are frequently associated with treatment-emergent sexual dysfunction (TESD). Vortioxetine, which was approved for patients with major depressive disorder (MDD), has a receptor profile that suggests limited impact on...
10.
Naik H, Chan S, Vakilynejad M, Chen G, Loft H, Mahableshwarkar A, et al.
Basic Clin Pharmacol Toxicol
. 2015 Nov;
118(5):344-55.
PMID: 26525043
Vortioxetine is approved for the treatment of major depressive disorder (MDD). This analysis aimed to develop pharmacokinetic (PK) and PK/Efficacy models to evaluate the exposure-response relationship for vortioxetine in patients...